New hope for rare, Tough-to-Treat cancers in clinical trial
NCT ID NCT06444880
Summary
This study is testing whether a new drug called ubamatamab, given alone or combined with an existing drug (cemiplimab), can help control two rare and aggressive cancers: renal medullary carcinoma and epithelioid sarcoma. It is for adults whose cancer has worsened after at least one prior treatment. The main goal is to see if the treatment can shrink tumors or stop them from growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMARCB1-DEFICIENT MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.